Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LRMR Stock 12 Month Forecast
Average Price Target
$21.00
▲(332.10% Upside)
| Highest Price Target$33.00 | Average Price Target$21.00 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$33
Buy
579.01%
Upside
Reiterated
09/16/25
Guggenheim
$26
Buy
434.98%
Upside
Reiterated
09/15/25
Leerink Partners
$25
Buy
414.40%
Upside
Reiterated
09/03/25
We are previewing the Phase 2 OLE data expected in September. The initial 50mg data expected in September 2025 is one of the many pieces of information LRMR is pulling together in hopes to file nomlabofusp under an accelerated approval pathway in 2Q26. With a written correspondence from the FDA, we have a clearer path toward achieving this goal. Some of the data recommended by the agency may be less needle-moving for the stock but remain crucial for pursuing an accelerated approval pathway. An example that falls under this category is data supporting a relationship between increased skin frataxin and relevant tissues such as the heart, dorsal root ganglion, and skeletal muscle (Toni et al., 2025). Other necessary data are considered more important for the stock, such as the initial Phase 2 OLE data from patients dosed with 50mg, which we expect to get in September.
William Blair
―
Buy
―
Reiterated
08/29/25
Citizens JMP
$18
Buy
270.37%
Upside
Reiterated
08/19/25
Citi
$12
Buy
146.91%
Upside
Reiterated
08/19/25
Oppenheimer
$26
Buy
434.98%
Upside
Reiterated
08/18/25
On 8/14, Larimar (LRMR) announced 2Q25 financials and provided a business update. We reiterate Outperform.
Truist Financial
$18
Buy
270.37%
Upside
Reiterated
08/14/25
JonesTrading
$12→$10
Buy
105.76%
Upside
Reiterated
08/04/25
Wedbush
$17→$15
Buy
208.64%
Upside
Reiterated
06/24/25
Robert W. Baird
$13→$10
Buy
105.76%
Upside
Reiterated
03/25/25
H.C. Wainwright
$15→$16
Buy
229.22%
Upside
Reiterated
03/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$33
Buy
579.01%
Upside
Reiterated
09/16/25
Guggenheim
$26
Buy
434.98%
Upside
Reiterated
09/15/25
Leerink Partners
$25
Buy
414.40%
Upside
Reiterated
09/03/25
We are previewing the Phase 2 OLE data expected in September. The initial 50mg data expected in September 2025 is one of the many pieces of information LRMR is pulling together in hopes to file nomlabofusp under an accelerated approval pathway in 2Q26. With a written correspondence from the FDA, we have a clearer path toward achieving this goal. Some of the data recommended by the agency may be less needle-moving for the stock but remain crucial for pursuing an accelerated approval pathway. An example that falls under this category is data supporting a relationship between increased skin frataxin and relevant tissues such as the heart, dorsal root ganglion, and skeletal muscle (Toni et al., 2025). Other necessary data are considered more important for the stock, such as the initial Phase 2 OLE data from patients dosed with 50mg, which we expect to get in September.
William Blair
―
Buy
―
Reiterated
08/29/25
Citizens JMP
$18
Buy
270.37%
Upside
Reiterated
08/19/25
Citi
$12
Buy
146.91%
Upside
Reiterated
08/19/25
Oppenheimer
$26
Buy
434.98%
Upside
Reiterated
08/18/25
On 8/14, Larimar (LRMR) announced 2Q25 financials and provided a business update. We reiterate Outperform.
Truist Financial
$18
Buy
270.37%
Upside
Reiterated
08/14/25
JonesTrading
$12→$10
Buy
105.76%
Upside
Reiterated
08/04/25
Wedbush
$17→$15
Buy
208.64%
Upside
Reiterated
06/24/25
Robert W. Baird
$13→$10
Buy
105.76%
Upside
Reiterated
03/25/25
H.C. Wainwright
$15→$16
Buy
229.22%
Upside
Reiterated
03/25/25
Best Analysts Covering Larimar Therapeutics
1 Month
xxx
Success Rate
5/8 ratings generated profit
Average Return
+11.01%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +11.01% per trade.
3 Months
xxx
Success Rate
6/8 ratings generated profit
Average Return
+28.86%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +28.86% per trade.
1 Year
Success Rate
17/25 ratings generated profit
Average Return
+33.66%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 68.00% of your transactions generating a profit, with an average return of +33.66% per trade.
2 Years
xxx
Success Rate
6/10 ratings generated profit
Average Return
+11.65%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +11.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LRMR Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
11
10
7
18
15
Buy
6
5
5
6
4
Hold
2
2
2
0
0
Sell
4
3
0
0
0
Strong Sell
0
0
0
0
0
total
23
20
14
24
19
Each month's total comprises the sum of three months' worth of ratings.
LRMR Financial Forecast
LRMR Stock Forecast FAQ
What is LRMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 21.00.
What is LRMR’s upside potential, based on the analysts’ average price target?
Larimar Therapeutics, Inc. has 332.10% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LRMR a Buy, Sell or Hold?
Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Larimar Therapeutics, Inc.’s price target?
The average price target for Larimar Therapeutics, Inc. is 21.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $33.00 ,the lowest forecast is $10.00. The average price target represents 332.10% Increase from the current price of $4.86.
The highest analyst price target is $33.00 ,the lowest forecast is $10.00. The average price target represents 332.10% Increase from the current price of $4.86.
What do analysts say about Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of LRMR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.